09/15/2025

Recent Oncology Related FDA Approvals and Expanded Indications

FDA Approves AstraZeneca’s Koselugo (selumetinib) for the Treatment of Pediatric Patients 1 Year of Age and Older With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable PN

FDA Approves Johnson & Johnson's Nlexzo™ (gemcitabine intravesical system) for the Treatment of Adult Patients with Bacillus Calmette-Guérin NMIBC With Carcinoma in situ

More Info